Program for Appropriate Technology in Health (PATH), Seattle, WA 98121, USA.
Trends Biotechnol. 2012 Jan;30(1):45-54. doi: 10.1016/j.tibtech.2011.06.015. Epub 2011 Jul 26.
A CD4 T-lymphocyte count determines eligibility for antiretroviral therapy (ART) in patients recently diagnosed with HIV and also monitors the efficacy of ART treatment thereafter. ART slows the progression of HIV to AIDS. In the developing world, CD4 tests are often performed in centralized laboratories, typically in urban areas. The expansion of ART programs into rural areas has created a need for rapid CD4 counting because logistical barriers can delay the timely dissemination of test results and affect patient care through delay in intervention or loss of follow-up care. CD4 measurement at the point-of-care (POC) in rural areas could help the facilitation of ART and monitoring of treatment. This review highlights recent technology developments with applications towards determining CD4 counts at the POC.
CD4 淋巴细胞计数可决定新近诊断出 HIV 的患者是否有资格接受抗逆转录病毒治疗(ART),并在随后监测 ART 治疗的效果。ART 可减缓 HIV 向艾滋病的进展。在发展中国家,CD4 检测通常在集中式实验室进行,通常在城市地区。ART 项目向农村地区的扩展需要快速进行 CD4 计数,因为后勤障碍可能会延迟及时发布检测结果,从而通过延迟干预或失去后续护理而影响患者护理。在农村地区进行即时护理点(POC)的 CD4 测量有助于促进 ART 并监测治疗效果。本综述强调了最近在应用于 POC 确定 CD4 计数方面的技术发展。